Increased MIF Levels in Primary Sjögren's Syndrome
Author Information
Author(s): Willeke Peter, Gaubitz Markus, Schotte Heiko, Maaser Christian, Domschke Wolfram, Schlüter Bernhard, Becker Heidemarie
Primary Institution: Muenster University Hospital
Hypothesis
The study aims to analyze levels of macrophage migration inhibitory factor (MIF) in patients with primary Sjögren's syndrome and examine its associations with clinical, serological, and immunological variables.
Conclusion
MIF levels are significantly increased in patients with primary Sjögren's syndrome, particularly in those with hypergammaglobulinemia.
Supporting Evidence
- MIF levels were significantly higher in patients with primary Sjögren's syndrome compared to healthy controls.
- Patients with hypergammaglobulinemia had increased MIF levels.
- There was a negative correlation between MIF levels and the number of IL-10-secreting PBMC.
Takeaway
This study found that people with a specific autoimmune disease have higher levels of a protein called MIF, which might be linked to their symptoms.
Methodology
MIF was measured in serum samples from patients with primary Sjögren's syndrome using ELISA, and various cytokines were analyzed using ELISPOT assays.
Limitations
The study did not include patients on glucocorticoids, and the influence of other medications on MIF levels was not fully explored.
Participant Demographics
The study included 76 patients with primary Sjögren's syndrome, predominantly female (73 females, 3 males), with a mean age of 49.2 years.
Statistical Information
P-Value
p < 0.01
Statistical Significance
p < 0.01
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website